跳到正文
原文
MedPage Today·· 8 天前精选AI 评分75

评估和管理HIV患者更高的心血管疾病风险

Assessing and Managing HIV's Higher Heart Disease Risks

AI 导读

HIV患者心血管疾病风险是传统因素的两倍,随机对照试验REPRIEVE显示他汀类药物可降低36%的心血管事件风险。美国心脏协会等机构发布了针对HIV患者的他汀类药物使用指南。

推荐理由

介绍了HIV患者心血管疾病风险的研究进展,特别是关于使用他汀类药物的随机对照试验结果。

正文 · 原文

— People with HIV are twice as likely to develop cardiovascular disease

November 11, 2026 • 4 min read

Understanding how HIV can shape cardiovascular disease risk may help clinicians tailor care to patients' needs, which starts with statins for most adults with HIV.

"HIV holds its own as a risk factor for developing cardiovascular disease," Virginia Triant, MD, MPH, of Massachusetts General Hospital in Boston, said in a presentation at the IDWeek annual meeting.

A 2018 meta-analysis showed that people living with HIV were twice as likely to develop cardiovascular disease as those without HIV, Triant observed. Those with HIV also faced greater risks of myocardial infarction and stroke she added, putting HIV nearly on par with the cardiovascular relative risks found in the INTERHEART study for hypertension, diabetes, and smoking.

Traditional factors play a part in the elevated cardiovascular risks linked to HIV. People with HIV have greater rates of hypertension, diabetes, and dyslipidemia than their HIV-negative counterparts, Triant noted. Research also shows an 85% lifetime history of smoking among those with HIV.

ART and Risk

That doesn't explain the whole story, Triant pointed out. Antiretroviral therapy brings its own set of cardiovascular risks.

Early protease inhibitors like darunavir were linked with cumulative myocardial infarction risks, and recent use of the nucleoside reverse transcriptase inhibitor abacavir was tied to increased myocardial infarction risk. It's not clear whether integrase strand transfer inhibitors also boost cardiovascular risk, with conflicting results from the RESPOND and HIV-CAUSAL studies.

After accounting for traditional risk factors and antiretroviral therapy, there's still a missing piece to the cardiovascular risk puzzle, Triant said. That piece may be the inflammation that comes with HIV.

The SMART study pointed to inflammation's role in cardiovascular disease, she noted. An analysis of data from the REPRIEVE study reinforced inflammation's role, even in people with well-controlled HIV and low to moderate cardiovascular risk.

Tailored Treatment

Despite growing understanding of how HIV uniquely shapes cardiovascular risk, "this has not until very recently translated into differing and tailored clinical guidance for people with HIV," Triant stated. "I really see this as a challenge in delivering equitable care for cardiovascular care for people living with HIV."

Existing cardiovascular risk prediction scores for the general population fall short among people with HIV, incorporating only traditional risk factors without including HIV-related factors, Triant said. Even among those with HIV, cardiovascular risk varies by sex, race, ethnicity, and geographic location.

Among those with HIV, the Pooled Cohort Equations (PCE) that debuted in 2013 underestimated cardiovascular risk in women and those in low to moderate risk groups. The more comprehensive 2023 PREVENT equations mirrored the PCE risk underestimation for people with HIV, with major adverse cardiovascular events (MACE) rates greater than PREVENT predictions.

Given underestimated risk, people with HIV have been less likely to receive cardiovascular preventive care that matches guidelines, Triant said. The guidelines for the general population are also less than what's needed for people with HIV, she said.

That began to change with cholesterol guidelines from the American Health Association (AHA) and other groups that added consideration of HIV as a cardiovascular disease risk factor. A 2019 AHA scientific statement that specifically focused on people with HIV highlighted risk-enhancing factors such as prolonged viremia, low CD4 counts, delays in starting antiretroviral therapy (ART), and metabolic syndrome.

Still, "what was really missing from the field was a large trial with robust data to support a recommendation for cardiovascular prevention for people with HIV," Triant said.

Universal Recommendation

Then came REPRIEVE in 2023. That phase III clinical trial included only people with HIV on ART who had low to moderate cardiovascular disease risk and didn't meet general guidelines' thresholds for statin therapy. REPRIEVE showed that statin therapy was linked to a 36% reduction in MACE risk compared with placebo.

These results weren't driven by a subgroup. "It was reduction whether you looked by demographics, or traditional risk factors, or traditional HIV-related factors," Triant explained.

REPRIEVE was the first randomized trial that showed a cardiovascular prevention benefit that was different from the general population. "This is really paradigm-shifting," she noted. A CDC analysis found that full implementation of REPRIEVE's approach in people with HIV and low to moderate cardiovascular disease risk could lead to 7,418 fewer first major adverse cardiovascular events over 5 years.

The REPRIEVE findings have spurred practice-changing guidelines for people with HIV, Triant said.

In 2024, an HHS panel rolled out recommendations calling for daily moderate-intensity statins in people with HIV ages 40 to 75 years with low to intermediate (less than 20%) 10-year risk of atherosclerotic cardiovascular disease (ASCVD). In those with less than 5% risk, the HHS panel favored starting at least moderate-intensity statins.

The American College of Cardiology and other societies followed that with a dyslipidemia guideline in 2026 that recommended that everyone with HIV ages 40 to 75 years on ART receive statin therapy to reduce ASCVD event risk and slow coronary atherosclerosis.

"This is really a striking recommendation, and an important one for the field," Triant explained. "Notably, this is regardless of calculated baseline risk, regardless of LDL, for people in this age group."

Clinicians might want to consider starting statins at age 30 for those with HIV, she added. "I would strongly consider HIV to be an ASCVD risk enhancer, even at that age, even though we don't have the trial data," Triant said.

Even with these newly tailored guidelines, implementation will be a challenge, she noted. Statin uptake in people with HIV was suboptimal before REPRIEVE, with 80% of patients eligible for statins under earlier guidelines not getting them.

"Dismantling disparities that we know exist in cardiovascular prevention and care remains a critical challenge," Triant said. "The recent guidelines are likely to be practice-changing for people with HIV, but only if implemented on a broad scale."

来源:MedPage Today · medpagetoday.com